Theranostic Agent Linker Cleavage for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drugs and treatment agents often cause unwanted side effects due to their systemic action, affecting non-targeted cells and tissues, leading to off-target effects and systemic toxicities.
Innovation Solution
Development of theranostic agents comprising a bioactive component, a detectable component, and a targeting component linked by a linker, which is specifically activated and released at the target site, allowing for targeted delivery and monitoring of therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs are administered systemically, then therapeutic effects are achieved, but off-target effects and systemic toxicities occur
Solution Approach 1:
The patent segments the drug delivery system into distinct functional components: a targeting moiety that directs the agent to specific cells, a linker that connects and protects the drug, and a detectable moiety for monitoring. This segmentation allows the drug to be delivered systemically while only becoming active at the target site, resolving the contradiction between achieving therapeutic effects and avoiding systemic toxicities.
Solution Approach 2:
The patent introduces an intermediary linker component that temporarily holds the drug in an inactive state during systemic circulation. The linker is designed to be cleaved by specific enzymes at the target site, thereby mediating the transition from systemic delivery to localized activation. This intermediary mechanism prevents off-target effects while ensuring therapeutic efficacy at the intended site.
2Object-affected harmful factors
If drugs are delivered to specific cells through targeting, then systemic toxicities are reduced, but delivery precision and monitoring capability are required
Solution Approach 1:
The patent combines multiple functions into a single theranostic agent: the targeting moiety provides cell-specific delivery, the linker enables controlled activation, and the detectable moiety allows real-time monitoring. This multi-functionality ensures that the agent not only achieves precise delivery to reduce off-target effects but also provides built-in capability for verifying delivery precision through detection of the detectable moiety at the target site.
3Ease of operation
If theranostic agents with multiple components are developed, then targeted delivery and monitoring are enabled, but device complexity increases
Solution Approach 1:
The patent merges the therapeutic and diagnostic functions into a single integrated theranostic agent. The targeting moiety, linker, and detectable moiety are covalently connected in one molecular construct, eliminating the need for separate administration of multiple agents. This merging approach enables monitoring capability while managing complexity by using a unified agent that can be administered and tracked as a single entity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables specific therapeutic benefits with reduced systemic toxicities by ensuring that drugs are delivered only to targeted cells or tissues, minimizing off-target effects and allowing for real-time monitoring of therapeutic efficacy.
Implementation Method 1
When the linker is broken (e.g., by activities such as esterases or other enzymes associated with the particular targeted classes or types of cells), the drug and the quantifiable fluorescent reporter are released
Data Source
AI summary
Provided herein is technology relating to theranostic agents and particularly, but not exclusively, to compositions comprising cell-specific theranostic agents and associated methods and systems for using the cell-specific theranostic agents to treat subjects.